| [1] |
NCD Risk Factor Collaboration (NCD-RISC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults [J]. Lancet (London, England), 2024, 403(10431): 1027-1050.
|
| [2] |
Ghiassi S, Morton JM. Safety and efficacy of bariatric and metabolic surgery [J]. Current Obesity Reports, 2020, 9(2): 159-164.
|
| [3] |
Jirapinyo P, Hadefi A, Thompson CC, et al. American Society for Gastrointestinal Endoscopy-European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity [J]. Endoscopy, 2024, 56(6): 437-456.
|
| [4] |
Perdomo CM, Cohen RV, Sumithran P, et al. Contemporary medical, device, and surgical therapies for obesity in adults [J]. Lancet (London, England), 2023, 401(10382): 1116-1130.
|
| [5] |
Brajcich BC, Hungness ES. Sleeve Gastrectomy[J]. JAMA, 2020, 324(9): 908.
|
| [6] |
Anhê FF, Zlitni S, Zhang SY, et al. Human gut microbiota after bariatric surgery alters intestinal morphology and glucose absorption in mice independently of obesity [J]. Gut, 2023, 72(3): 460-471.
|
| [7] |
Nierop FS Van, Jonge C De, Kulik W, et al. Duodenal-jejunal lining increases postprandial unconjugated bile acid responses and disrupts the bile acid-FXR-FGF19 axis in humans [J]. Metabolism - Clinical and Experimental, 2019, 93: 25-32.
|
| [8] |
Mohapatra S, Gangadharan K, Pitchumoni CS. Malnutrition in obesity before and after bariatric surgery [J]. Disease-a-month: DM, 2020, 66(2): 100866.
|
| [9] |
Marincola G, Velluti V, Voloudakis N, et al. Medium-term nutritional and metabolic outcome of Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy (SADI-S) [J]. Nutrients, 2023, 15(3): 742.
|
| [10] |
Pereira SS, Guimarães M, Almeida R, et al. Biliopancreatic diversion with duodenal switch (BPD-DS) and single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) result in distinct post-prandial hormone profiles [J]. International Journal of Obesity (2005), 2019, 43(12): 2518-2527.
|
| [11] |
Steenackers N, Vanuytsel T, Augustijns P, et al. Adaptations in gastrointestinal physiology after sleeve gastrectomy and Roux-en-Y gastric bypass [J]. The Lancet. Gastroenterology & Hepatology, 2021, 6(3): 225-237.
|
| [12] |
Sandoval DA, Patti ME. Glucose metabolism after bariatric surgery: implications for T2DM remission and hypoglycaemia [J]. Nature Reviews. Endocrinology, 2023, 19(3): 164-176.
|
| [13] |
Cavin JB, Couvelard A, Lebtahi R, et al. Differences in alimentary glucose 1 absorption and intestinal disposal of blood glucose Following Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy [J]. Gastroenterology, 2015, 150(2): 454.
|
| [14] |
Koenis MMG, Papasavas PK, Janssen RJ, et al. Brain responses to anticipatory cues and milkshake taste in obesity, and their relationship to bariatric surgery outcome [J]. NeuroImage, 2021, 245: 118623.
|
| [15] |
Van Rijswijk AS, Van Olst N, Schats W, et al. What is weight loss after bariatric surgery expressed in percentage total weight loss (%TWL)? A Systematic Review [J]. Obesity Surgery, 2021, 31(8): 3833-3847.
|
| [16] |
Pedersen JS, Rygg MO, Serizawa RR, et al. Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: a 12-month follow-up study with paired liver biopsies [J]. Journal of Clinical Medicine, 2021, 10(17): 3783.
|
| [17] |
Svanevik M, Lorentzen J, Borgeraas H, et al. Patient-reported outcomes, weight loss, and remission of type 2 diabetes 3 years after gastric bypass and sleeve gastrectomy (Oseberg); a single-centre, randomised controlled trial [J]. The Lancet. Diabetes & Endocrinology, 2023, 11(8): 555-566.
|
| [18] |
Salminen P, Grönroos S, Helmiö M, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on weight loss, comorbidities, and reflux at 10 years in adult patients with obesity [J]. JAMA Surgery, 2022, 157(8): 656-666.
|
| [19] |
Robert M, Poghosyan T, Maucort-Boulch D, et al. Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass at 5 years (YOMEGA): a prospective, open-label, non-inferiority, randomised extension study [J]. The Lancet. Diabetes & Endocrinology, 2024, 12(4): 267-276.
|
| [20] |
Salte OBK, Olbers T, Risstad H, et al. Ten-year outcomes following Roux-en-Y Gastric Bypass vs Duodenal Switch for high Body Mass Index: a randomized clinical trial [J]. JAMA network open, 2024, 7(6): e2414340.
|
| [21] |
Gebellí JP, Lazzara C, De Gordejuela AGR, et al. Duodenal Switch vs. Single-Anastomosis Duodenal Switch (SADI-S) for the treatment of grade IV obesity: 5-year outcomes of a multicenter prospective cohort comparative study [J]. Obesity Surgery, 2022, 32(12): 3839-3846.
|
| [22] |
Hu Z, Sun J, Li R, et al. A comprehensive comparison of LRYGB and LSG in obese patients including the effects on QoL, comorbidities, weight loss, and complications: a systematic review and Meta-analysis [J]. Obesity Surgery, 2020, 30(3): 819-827.
|
| [23] |
Yashkov Y, Bordan N, Torres A, et al. SADI-S 250 vs Roux-en-Y Duodenal Switch (RY-DS): Results of 5-year observational study [J]. Obesity Surgery, 2021, 31(2): 570-579.
|
| [24] |
Kavanagh R, Smith J, Avgenackis E, et al. A comparison of the effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on body mass composition as measured by air displacement plethysmography [J]. Obesity Surgery, 2020, 30(2): 451-455.
|
| [25] |
Barthold D, Brouwer E, Barton LJ, et al. Minimum threshold of bariatric surgical weight loss for initial diabetes remission [J]. Diabetes Care, 2022, 45(1): 92-99.
|
| [26] |
Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial [J]. Lancet (London, England), 2015, 386(9997): 964-973.
|
| [27] |
Nussbaumerova B, Rosolova H. Obesity and dyslipidemia [J]. Current Atherosclerosis Reports, 2023, 25(12): 947-955.
|
| [28] |
Wolfe BM, Kvach E, Eckel RH. Treatment of obesity: weight loss and bariatric surgery [J]. Circulation research, 2016, 118(11): 1844-1855.
|
| [29] |
Schauer DP, Feigelson HS, Koebnick C, et al. Bariatric surgery and the risk of cancer in a large multisite cohort [J]. Annals of Surgery, 2019, 269(1): 95-101.
|
| [30] |
Ghiassi S, Morton JM. Safety and efficacy of bariatric and metabolic surgery [J]. Current Obesity Reports, 2020, 9(2): 159-164.
|
| [31] |
Musella M, Berardi G, Vitiello A, et al. Vitamin D deficiency in patients with morbid obesity before and after metabolic bariatric surgery [J]. Nutrients, 2022, 14(16): 3319.
|
| [32] |
Arterburn D, Wellman R, Emiliano A, et al. Comparative effectiveness and safety of bariatric procedures for weight loss: A PCORnet Cohort Study [J]. Annals of Internal Medicine, 2018, 169(11): 741-750.
|
| [33] |
Saunders KH, Igel LI, Saumoy M, et al. Devices and endoscopic bariatric therapies for obesity [J]. Current Obesity Reports, 2018, 7(2): 162-171.
|
| [34] |
Vargas EJ, Bazerbachi F, Calderon G, et al. Changes in time of gastric emptying after surgical and endoscopic bariatrics and weight loss: a systematic review and Meta-analysis [J]. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association, 2020, 18(1): 57-68.e5.
|
| [35] |
Trang J, Lee SS, Miller A, et al. Incidence of nausea and vomiting after intragastric balloon placement in bariatric patients - a systematic review and meta-analysis [J]. International Journal of Surgery (London, England), 2018, 57: 22-29.
|
| [36] |
Abdulla M, Mohammed N, Alqamish J. Overview on the endoscopic treatment for obesity: a review [J]. World Journal of Gastroenterology, 2023, 29(40): 5526-5542.
|
| [37] |
Kim J, Azagury D, Eisenberg D, et al. ASMBS position statement on prevention, detection, and treatment of gastrointestinal leak after gastric bypass and sleeve gastrectomy, including the roles of imaging, surgical exploration, and nonoperative management [J]. Surgery for Obesity and Related Diseases: Official Journal of the American Society for Bariatric Surgery, 2015, 11(4): 739-748.
|
| [38] |
Abu Dayyeh BK, Acosta A, Camilleri M, et al. Endoscopic Sleeve Gastroplasty alters gastric physiology and induces loss of body weight in obese individuals [J]. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, 2017, 15(1): 37-43.e1.
|
| [39] |
Li P, Ma B, Gong S, et al. Efficacy and safety of endoscopic sleeve gastroplasty for obesity patients: a meta-analysis [J]. Surgical Endoscopy, 2020, 34(3): 1253-1260.
|
| [40] |
Farha J, Mcgowan C, Hedjoudje A, et al. Endoscopic sleeve gastroplasty: suturing the gastric fundus does not confer benefit [J]. Endoscopy, 2021, 53(7): 727-731.
|
| [41] |
Hajifathalian K, Mehta A, Ang B, et al. Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty [J]. Gastrointestinal Endoscopy, 2021, 93(5): 1110-1118.
|
| [42] |
Yang H, Hu B. Potential therapeutic mechanism of duodenal mucosal resurfacing [J]. Gastrointestinal Endoscopy, 2021, 94(5): 1015-1016.
|
| [43] |
Meiring S, Meessen ECE, Van Baar ACG, et al. Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes [J]. American Journal of Physiology - Endocrinology and Metabolism, 2022, 322(2): e132-e140.
|
| [44] |
Mingrone G, Van Baar AC, Devière J, et al. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial [J]. Gut, 2022, 71(2): 254-264.
|
| [45] |
Musso G, Pinach S, Saba F, et al. Endoscopic duodenal mucosa ablation techniques for diabetes and nonalcoholic fatty liver disease: a systematic review [J]. Med (New York, N.Y.), 2024, 5(7): 735-758.e2.
|
| [46] |
Van Baar ACG, Holleman F, Crenier L, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study [J]. Gut, 2020, 69(2): 295-303.
|
| [47] |
Ryder REJ, Laubner K, Benes M, et al. Endoscopic Duodenal-Jejunal Bypass Liner treatment for Type 2 Diabetes and obesity: glycemic and cardiovascular disease risk factor improvements in 1,022 patients treated worldwide [J]. Diabetes Care, 2023, 46(4): e89-e91.
|
| [48] |
Hollenbach M, Feisthammel J, Prettin C, et al. Weight-loss endoscopy trial: a multicenter, randomized, controlled trial comparing weight loss in endoscopically implanted Duodenal-Jejunal Bypass Liners versus Intragastric Balloons versus a sham procedure [J]. Digestion, 2024, 105(6): 468-479.
|
| [49] |
Barrichello S, Ribeiro IB, De Souza TF, et al. Gastric emptying and its correlation with weight loss and Body Mass Index in patients with an Intragastric Balloon: a prospective study with six years of follow-up [J]. Cureus, 14(12): e32599.
|
| [50] |
Singh S, De Moura DTH, Khan A, et al. Intragastric Balloon versus Endoscopic Sleeve Gastroplasty for the treatment of obesity: a systematic review and Meta-analysis [J]. Obesity Surgery, 2020, 30(8): 3010-3029.
|
| [51] |
Choy K, Abbitt D, Kovar A, et al. Weighing your options-intragastric balloon versus semaglutide [J]. Surgical Endoscopy, 2024, 38(10): 6070-6075.
|
| [52] |
Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery [J]. Obesity Surgery, 2023, 33(1): 3-14.
|
| [53] |
Simons M, Sharaiha RZ. Updates in metabolic bariatric endoscopy [J]. Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society, 2024, 36(2): 107-115.
|
| [54] |
Roth AE, Thornley CJ, Blackstone RP. Outcomes in bariatric and metabolic surgery: an updated 5-year review [J]. Current Obesity Reports, 2020, 9(3): 380-389.
|